Is TB-500 Legal in Ohio? Federal Law, State Rules, and How to Get It

What TB-500 Actually Is

TB-500 is a synthetic, 17-amino-acid fragment of thymosin beta-4, a naturally occurring 43-amino-acid protein encoded by the TMSB4X gene. Thymosin beta-4 was first isolated from bovine thymus tissue in 1966. The peptide modulates actin polymerization, reduces inflammation, and promotes cell migration in preclinical studies. It is not a hormone, not a steroid, and not a classic small-molecule drug.

Mechanism at the Cellular Level

Thymosin beta-4 binds G-actin monomers with high affinity, sequestering them and altering cytoskeletal dynamics. A 2010 study in the Journal of Molecular Medicine found that thymosin beta-4 accelerated corneal wound healing in rodent models by upregulating laminin-5 and integrin expression (1). That mechanistic work is among the most-cited preclinical rationale for TB-500's proposed tissue-repair properties.

Current Research Status

No Phase III randomized controlled trial has yet established clinical efficacy of synthetic TB-500 in humans for any indication. RegeneRx Biopharmaceuticals completed Phase II trials of Tβ4 (RGN-137, RGN-259) for dry eye and skin ulcers; those trials used the full 43-amino-acid sequence, not the TB-500 fragment specifically (2). The distinction matters legally because FDA evaluates each molecular entity separately.

Federal Legal Framework: What the FDA Actually Says

The FDA has not approved any TB-500 drug product. Under the Federal Food, Drug, and Cosmetic (FD&C) Act, a substance that is intended to diagnose, cure, treat, or prevent disease is a drug, regardless of whether it carries a brand name (3). Selling TB-500 with therapeutic claims without an approved New Drug Application (NDA) or Abbreviated NDA (ANDA) violates 21 U.S.C. § 355.

The FDA's Bulk-Substances Compounding Lists

The FD&C Act, as amended by the Drug Quality and Security Act (DQSA) of 2013, created two separate compounding pathways (4):

• 503A pharmacies (traditional, patient-specific): May compound from bulk substances that appear on the FDA's 503A Bulks List, are components of FDA-approved drugs, or have a United States Pharmacopeia (USP) or National Formulary (NF) monograph.
• 503B outsourcing facilities (large-scale, hospital supply): Must use bulk substances on the separate 503B Bulks List.

As of January 2025, thymosin beta-4 and its synthetic fragment TB-500 do not appear on either the 503A or 503B nominated bulks lists as approved for compounding (5). The FDA has not issued a final rule prohibiting their use either, leaving them in an unresolved "under review" category for many compounding pharmacies that have operated on the basis of historic practice.

The Research Chemical Pathway

Many vendors sell TB-500 online labeled "for research use only, not for human consumption." This label does not create a legal exemption. The FDA's position, stated explicitly in its 2017 guidance on research chemicals (6), is that labeling alone does not change a product's regulatory status if it is marketed in a context suggesting human use. Vendors who ship TB-500 with dosing instructions risk enforcement under FD&C Act misbranding provisions (21 U.S.C. § 352) and unapproved-new-drug provisions (21 U.S.C. § 355).

Ohio State Law: What the Board of Pharmacy Governs

Ohio does not have a state statute that independently schedules or bans TB-500. The Ohio Revised Code (ORC) Chapter 3719 lists controlled substances; thymosin beta-4 and TB-500 do not appear on that schedule (7). The absence of a state prohibition does not, however, create a green light for unregulated sale.

Ohio Board of Pharmacy Compounding Rules

The Ohio State Board of Pharmacy regulates pharmacy compounding under Ohio Administrative Code (OAC) Chapter 4729-16. Ohio-licensed 503A pharmacies must follow USP <795> (non-sterile) and USP <797> (sterile) standards. The Board requires that any compounded drug be prepared pursuant to a valid prescription for an identified patient (8).

A 2022 Ohio Board of Pharmacy advisory letter reminded licensees that bulk substances not on the FDA's approved list "require careful review of federal guidance before dispensing." The Board has not issued a TB-500-specific prohibition, but it has the authority to discipline a pharmacist for compounding a product deemed an unapproved new drug under federal law.

Ohio Medical Practice Act

Under ORC § 4731.22, an Ohio physician who prescribes a product for a purpose not supported by credible clinical evidence may face professional discipline. Prescribing TB-500 off-label is not automatically prohibited, but the physician bears the burden of documenting medical necessity and informed consent. Ohio's off-label prescribing rules generally mirror the standard of care framework described by the American Medical Association (9).

The Gray Zone Explained: Why Legal Status Is Genuinely Uncertain

Three factors create the gray zone that practitioners and patients encounter.

Factor 1: FDA Enforcement Discretion

The FDA does not prosecute every unapproved peptide compound. Its enforcement priorities, documented in the 2020 Compounding Policy Priorities Plan (10), focus on products that present safety risks, are essentially copies of commercially available drugs, or are produced in unsanitary conditions. TB-500 does not compete with an approved product, which has historically reduced enforcement attention. That could change if the FDA finalizes its 503A bulks review.

Factor 2: WADA and Sports Prohibition

The World Anti-Doping Agency (WADA) has prohibited thymosin beta-4 since 2012 under the "Peptide Hormones, Growth Factors, Related Substances, and Mimetics" category (11). Ohio athletes subject to WADA, NCAA, or USADA testing face sanctions even if state law does not prohibit personal possession. This prohibition is independent of FDA or Ohio pharmacy law.

Factor 3: Import and Interstate Shipping Risk

Importing TB-500 from overseas manufacturers for personal use triggers FDA import provisions under 21 U.S.C. § 381. The FDA's personal importation policy covers some low-risk situations, but it applies to FDA-approved foreign drugs, not unapproved compounds (12). Packages are routinely detained at customs.

How a Licensed Ohio Prescriber Can Legally Order TB-500

The following framework reflects current federal and Ohio law as of January 2025. It is intended as a clinical decision reference, not legal advice. Any prescriber should consult their malpractice carrier and the Ohio Board of Pharmacy before ordering.

Step 1: Establish a Valid Prescriber-Patient Relationship

Ohio requires a prescriber-patient relationship before issuing any prescription, including compounded medications. Since 2021, Ohio HB 341 has allowed telemedicine to satisfy this requirement provided a real-time audio-video visit occurs and the prescriber is licensed in Ohio (13).

Step 2: Identify a 503A-Compliant Compounding Pharmacy

The prescriber must identify an Ohio-licensed or out-of-state 503A pharmacy that has legal counsel supporting TB-500 compounding. Because TB-500 is not on the FDA's approved bulks list, the pharmacy's compliance team must verify that the specific bulk supplier holds a valid DEA registration (if applicable) and that the compound has a documented safety profile sufficient to defend against an unapproved-drug action.

Step 3: Document Medical Necessity

The prescriber's chart should include: the patient's diagnosis or clinical indication, a review of available evidence (including the RegeneRx Phase II data and relevant preclinical literature), a discussion of the lack of Phase III human trial data, and signed informed consent. The FDA has noted that "clinical need" documentation is a factor in enforcement discretion decisions (14).

Step 4: Write a Patient-Specific Prescription

The prescription must be patient-specific (not a standing office-use order) and must comply with ORC § 4729.01 labeling requirements. Dosing in clinical practice typically follows protocols derived from animal studies and early human reports; no FDA-approved label exists to reference.

Step 5: Confirm Pharmacy Sterile Standards

TB-500 is almost always administered by subcutaneous or intramuscular injection, making it a sterile preparation subject to USP <797>. The compounding pharmacy must hold a current USP <797> compliance record. Ohio Board inspectors check these records during site visits.

Realistic Dosing Context: What the Evidence Supports

No human dose-finding study for TB-500 has been published in a peer-reviewed journal as of January 2025. Preclinical cardiac repair studies used thymosin beta-4 at 150 mcg injected intraperitoneally in murine models (15). The RegeneRx Phase II dry-eye trial (RGN-259) used 0.1% topical Tβ4 applied four times daily for 28 days; that trial enrolled 72 participants and demonstrated statistically significant improvement in total ocular symptom score (P<0.05) compared to vehicle (16). Neither trial used injectable TB-500 in the fragment form sold commercially.

Practitioners who prescribe injectable TB-500 off-label typically cite the RegeneRx safety data as supporting tolerability of the Tβ4 peptide class broadly. That extrapolation has not been validated in a controlled trial, and patients should understand this gap before consenting.

Safety Profile: What Is Known

Thymosin beta-4 has been studied as a drug candidate for over 20 years without a serious adverse event signal emerging in formal trials, though the total human exposure data remains limited. A 2004 Phase I safety study of systemic Tβ4 in healthy volunteers (N=12) found no dose-limiting toxicities at doses up to 1,260 mcg/kg IV (17). Injection-site reactions (erythema, transient pain) are the most commonly self-reported adverse effects in online patient communities; these have not been systematically characterized in a controlled setting.

The primary safety concern with any unregulated compounded injectable is not the peptide itself but contamination, endotoxin load, and sterility failures at the compounding level. The FDA's 2012 New England Compounding Center (NECC) meningitis outbreak, which killed 64 patients, illustrates the consequences of sterility failures in compounded injectables (18).

Comparing Ohio to Federal Baseline: What Is Different at the State Level

Ohio does not have state-specific peptide regulations that diverge from the federal baseline. Unlike some states that have added peptides to their controlled substance analog schedules, Ohio has not done so for thymosin beta-4 or TB-500 as of January 2025. The practical result is that Ohio's legal environment for TB-500 is defined almost entirely by federal FDA and DEA frameworks rather than unique state law.

The Ohio Medical Board's standard-of-care requirements do add one layer: a physician disciplinary action in Ohio does not require a criminal conviction. The Board can sanction a prescriber for "departure from, or failure to conform to, the minimal standards of care" under ORC § 4731.22(B)(6), which means that prescribing a compound lacking Phase III human evidence carries professional risk even when no state statute explicitly bans it (19).

What Patients in Ohio Should Do Right Now

Patients seeking TB-500 in Ohio have three realistic paths, each with a different risk profile.

Path 1: Telehealth Prescription Through a Licensed Ohio Provider

This is the lowest-risk path. A board-certified physician licensed in Ohio evaluates the patient, documents the clinical rationale, and sends a patient-specific prescription to a 503A compounding pharmacy. The patient receives a sterile, labeled product. Cost ranges from roughly $80 to $200 per vial depending on concentration and pharmacy.

Path 2: In-Person Visit at an Ohio Integrative Medicine or TRT Clinic

Several Ohio-based clinics that specialize in peptide therapy, testosterone replacement, or regenerative medicine already have compounding pharmacy relationships. An in-person evaluation adds the benefit of physical examination findings in the medical record, which strengthens the medical-necessity documentation.

Path 3: Do Nothing Until Regulatory Clarity Improves

The FDA's ongoing 503A bulk-substances review may produce a final rule within the next 12 to 24 months that either approves or prohibits TB-500 for compounding. Patients who are not dealing with an urgent clinical indication may prefer to wait for that clarity rather than manage the current ambiguity.

Purchasing TB-500 from unregulated online vendors carries real risk: the product may be contaminated, under-dosed, or mislabeled, and the buyer has no recourse if harmed. A 2018 analysis published in JAMA Internal Medicine found that 28 of 44 dietary supplement products tested contained undisclosed active pharmaceutical ingredients (20). The same contamination risk applies to unregulated peptide vendors operating outside pharmacy oversight.